Korro Bio, Inc. (KRRO) AI Stock Analysis

Korro Bio, Inc. is a biopharmaceutical firm specializing in the discovery, development, and commercialization of genetic medicines through RNA editing. Based in Cambridge, Massachusetts, the company uses its proprietary OPERA platform to design therapies tailored to unmet therapeutic needs. Its lead preclinical candidate, KRRO-110, is designed to treat Alpha-1 Antitrypsin Deficiency (AATD), a genetic disorder marked by low levels of a protective blood protein. Beyond KRRO-110, Korro Bio is pursuing research programs targeting Parkinson's disease, Amyotrophic lateral sclerosis (ALS), severe alcohol-associated hepatitis, and diverse pain conditions.

Korro Bio's revenue has fluctuated historically, falling from $28.9M in FY2019 to $2.3M in FY2024 before increasing 181.5% to $6.4M in FY2025. Over the four-year period from FY2019 to FY2025, revenue registered a CAGR of -31.4%. Operating losses have expanded alongside clinical investment, with FY2025 operating margin at -1366.4% and net income at -$117.3M, driven by $65.6M in R&D expenses. For the trailing twelve months ended June 30, 2026, revenue stood at $2.4M, with quarterly revenue falling 43.1% year-over-year and trailing EPS at -$9.88.

As of June 30, 2026, Korro Bio held $115.0M in cash and short-term investments and $42.2M in total debt, resulting in net cash of $72.8M. Total assets stood at $163.4M against shareholders' equity of $103.2M. Liquidity remains supported by a current ratio of 9.55 and a debt-to-equity ratio of 0.41. In FY2025, the company used -$78.6M in operating cash flow and incurred $518,000 in capital expenditures, producing free cash flow of -$79.1M, while its share count expanded 2446.4% over five years.

Korro Bio carries a market capitalization of $125.0M and an enterprise value of $71.8M. The stock trades at a price-to-sales multiple of 52.5x and an EV-to-revenue multiple of 30.1x, significantly higher than the median of its US-listed Healthcare peers at 4.1x price-to-sales. Its price-to-book ratio is 1.4x. Over the past year, KRRO fell 82.5%, compared to a 16.8% gain for the S&P 500 (SPY). Over five years, the stock dropped 97.6% versus an 83.0% gain for the benchmark index.

Wall Street coverage includes 8 Strong Buy, 2 Buy, and 1 Hold ratings, with no Sell recommendations. The mean price target is $20.20, representing upside of 137.9% from the last close of $8.49. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $375,000 and EPS of -$5.23. For the following fiscal year, 8 analysts estimate revenue of $587,500 and EPS of -$4.42. The company beat EPS estimates in all of the last 4 quarters, with its next earnings release scheduled for November 11, 2026.

This page is an AI-written research summary of Korro Bio, Inc. (KRRO). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: KRRO income statement, KRRO balance sheet, KRRO key metrics, KRRO analyst forecast, KRRO chart. See the KRRO stock overview for the latest quote and news.